Funding

AdipoSeeds

Japan · Biotech

AdipoSeeds develops platelet-based regenerative medicine and platelet-processing technology.

Visit adiposeeds.co.jpFunding history

Product

The Tokyo biotechnology company uses cells derived from adipose tissue to produce platelet-like cells. Founded in 2016 from Keio University research, it is developing ADS-01 for hard-to-heal skin ulcers and ADS-02 for transfusion applications.

AdipoSeeds also works with Kohjin Bio on platelet-rich plasma processing for medical institutions. Its therapeutic programmes remain in development.

Funding history

1 round · 0 with disclosed amounts
AnnouncedRoundAmountInvestors
Strategic investmentUndisclosedKohjin Bio — ParticipantTOHO HOLDINGS CO — Participant

Investors

Kohjin BioJoined Strategic investmentTOHO HOLDINGS COJoined Strategic investment

Coverage

Oct 16, 2026AdipoSeeds · Strategic investment

Similar companies

Estuary BiotherapeuticsEstuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.$93M · Series A
MicrobioticaMicrobiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment.£36M · Series C first close
Acta PharmaceuticalsDevelops investigational medicines for early intervention in Alzheimer’s disease.$24M · Total seed financing
Sourcesprtimes.jp ↗